243 completed. 243 Phase 3, 16 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 243 | Completed 243 |
| Phase 2 | 16 | Completed 16 |
Follow Neoplasms, Nerve Tissue: new trials by email Literature Review of Neoplasms, Nerve Tissue trials Research Report on Neoplasms, Nerve Tissue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients Dapagliflozin placebo, Placebo, DexamethasoneGroup III (n=25) (Dexamethasone group) - Glioma, Dapagliflozin (Forxiga) | Phase 3 | Completed | Tanta University | 75 | 2025-01-20 | 2026-09-30 |
| Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma RPH-075, Keytruda® - Skin Melanoma | Phase 3 | Completed | R-Pharm | 266 | 2023-09-27 | 2026-07-15 |
| A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma ABP 206, FDA-licensed Nivolumab, EU-authorized Nivolumab - Melanoma | Phase 3 | Completed | Amgen | 256 | 2023-07-26 | 2026-03-27 |
| Tofacitinib in Recurrent GBM Patients Tofacitinib 10mg, Temozolomide, Lomustine - Glioblastoma | Phase 3 | Completed | University of Texas Southwestern Medical Center | 18 | 2022-10-07 | 2026-06-29 |
| A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection Nivolumab/rHuPH20, Nivolumab - Melanoma | Phase 3 | Completed | Bristol-Myers Squibb | 14 | 2022-08-02 | 2025-02-27 |
| Open-Label Study of 18F-mFBG for Imaging Neuroblastoma 18F-MFBG - Neuroblastoma | Phase 3 | Completed | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | 43 | 2021-11-18 | 2026-09-29 |
| A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 Enzastaurin Hydrochloride, Placebo, Temozolomide - Glioblastoma | Phase 3 | Completed | Denovo Biopharma LLC | 260 | 2020-12-16 | 2024-04-22 |
| Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma Gleolan - Meningioma | Phase 3 | Completed | NX Development Corp | 108 | 2020-10-28 | 2026-05-18 |
| Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors Al18F-NOTA-octreotide, PET/CT, PET/MR - Neuroendocrine Tumors | Phase 2 / Phase 3 | Completed | Universitaire Ziekenhuizen KU Leuven | 85 | 2020-10-07 | 2022-02-17 |
| Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab - Gliosarcoma, MGMT-Unmethylated Glioblastoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 159 | 2020-09-01 | 2026-04-22 |
| Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study Pembrolizumab, Lenvatinib, Placebo for lenvatinib - Malignant Melanoma | Phase 3 | Completed | Merck Sharp & Dohme LLC | 131 | 2020-07-14 | 2025-12-23 |
| Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors Continue PD-1/PD-L1 Inhibitors treatment, Discontinue PD-1/PD-L1-1 inhibitor - Advanced Solid Tumors, NSCLC | Phase 3 | Completed | Dan Zandberg | 161 | 2019-11-15 | 2025-12-11 |
| SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors 68Ga-DOTATATE PET/CT - Neuroendocrine Tumors | Phase 3 | Completed | Jewish General Hospital | 45 | 2019-10-01 | 2025-05-15 |
| Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) Pembrolizumab, Lenvatinib, Placebo for lenvatinib - Malignant Melanoma | Phase 3 | Completed | Merck Sharp & Dohme LLC | 674 | 2019-03-12 | 2026-02-09 |
| Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) Pembrolizumab (MK-3475) - Merkel Cell Carcinoma | Phase 3 | Completed | Merck Sharp & Dohme LLC | 55 | 2019-02-25 | 2025-05-28 |
| A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma NKTR-214, Nivolumab - Melanoma | Phase 3 | Completed | Bristol-Myers Squibb | 783 | 2018-09-21 | 2025-04-01 |
| Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes Dabrafenib, Trametinib - Malignant Melanoma | Phase 3 | Completed | Novartis Pharmaceuticals | 552 | 2018-08-29 | 2025-04-29 |
| Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE 64Cu-DOTATATE - Neuroendocrine Tumors | Phase 3 | Completed | Radiomedix, Inc. | 63 | 2018-08-23 | 2022-12-22 |
| Magnesium and Intraoperative Blood Loss in Meningioma Surgery Magnesium group, Normal saline group - Meningioma | Phase 3 | Completed | Mahidol University | 80 | 2018-08-01 | 2020-07-13 |
| Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases Lutetium Lu 177-DOTATATE - Neuroendocrine Tumors, Liver Metastases | Phase 2 / Phase 3 | Completed | Marnix Lam | 26 | 2018-08-01 | 2022-11-08 |
Showing 20 of 243. Sign in to see all of them.
Melanoma (81) · Glioblastoma (48) · Brain Neoplasms (26) · Neuroblastoma (24) · Astrocytoma (23) · Neoplasms (22) · Glioma (20) · Central Nervous System Neoplasms (18) · Neuroendocrine Tumors (18) · Gliosarcoma (16) · Sarcoma (14) · Neoplasm Metastasis (13) · Breast Neoplasms (11) · Fibrosarcoma (10) · Liposarcoma (10)
Neoplasms by Histologic Type (243) · Neoplasms, Germ Cell and Embryonal (230) · Neuroectodermal Tumors (230) · Neoplasms (221) · Neoplasms by Site (151) · Neoplasms, Glandular and Epithelial (124) · Neoplasms, Neuroepithelial (111) · Neuroendocrine Tumors (102) · Nevi and Melanomas (89) · Skin and Connective Tissue Diseases (88) · Skin Diseases (86) · Skin Neoplasms (72) · Nervous System Diseases (64) · Glioma (59)
Radiotherapy (33) · Temozolomide (29) · Dacarbazine (22) · Cyclophosphamide (20) · Carboplatin (19) · Etoposide (18) · Doxorubicin (17) · Vincristine (17) · Filgrastim (15) · Nivolumab (15) · Ipilimumab (14) · Cisplatin (13) · Lomustine (13) · Ifosfamide (11) · Granulocyte Colony-Stimulating Factor (10)
Bristol-Myers Squibb (16) · Children's Oncology Group (15) · European Organisation for Research and Treatment of Cancer - EORTC (13) · National Cancer Institute (NCI) (12) · Novartis Pharmaceuticals (10) · Hoffmann-La Roche (7) · Merck Sharp & Dohme LLC (6) · Radiation Therapy Oncology Group (6) · Assistance Publique - Hôpitaux de Paris (5) · Pfizer (4) · AstraZeneca (3) · Fred Hutchinson Cancer Center (3) · Institut Curie (3) · SWOG Cancer Research Network (3) · Alliance for Clinical Trials in Oncology (2)
United States (144) · Canada (92) · Germany (79) · France (77) · Australia (70) · United Kingdom (70) · Italy (66) · Netherlands (65) · Spain (60) · Switzerland (52) · Belgium (51) · Austria (42) · Poland (40) · Sweden (40) · Israel (38)
Roger Stupp, MD (5) · Lawrence E. Flaherty, MD (3) · Alberto S. Pappo, MD (2) · Brigitta Baumert, MD, PhD (2) · J. Gregory Cairncross, MD (2) · John M. Kirkwood, MD (2)
PMID 34225229, PMID 36346112, PMID 36653848, PMID 39504507, PMID 23054107, PMID 23504141, PMID 25667295, PMID 26446943, PMID 27864013, PMID 28662232, PMID 29023494, PMID 30053159, PMID 31166680, PMID 32691060, PMID 32746839, PMID 35344750, PMID 35489301, PMID 35731991, PMID 40306120, PMID 10549493, PMID 10882162, PMID 11464889, PMID 11586105, PMID 12101494, PMID 12165894, PMID 12192533, PMID 12880954, PMID 12932669, PMID 14665609, PMID 15234047, PMID 15251162, PMID 15459300, PMID 15465203, PMID 15727424, PMID 15758009, PMID 15758010, PMID 15890570, PMID 16033132, PMID 16129365, PMID 16203762, PMID 16321761, PMID 16520474, PMID 16735709, PMID 16782910, PMID 16782911, PMID 17005948, PMID 17429084, PMID 17549014, PMID 17609661, PMID 17634494
U10CA098543 (11), U10CA180886 (9), 2008 (4), 2018 (4), 2015 (3), 2016 (3), U10CA032102 (3), 2004 (2), 2005 (2), 2009 (2), U10CA021115 (2), U10CA180868 (2), 2014 (1), 2017 (1), P01CA023099 (1)